LATISSE® is a new prescription eyelash growth treatment, produced by Allergan, maker of Botox and leading global medical aesthetics company. The FDA recently approved LATISSE (bimatoprost ophthalmic solution) 0.03% for treatment of inadequate or insufficient eyelashes. LATISSE acts to help eyelashes grow longer, fuller and darker. LATISSE is the first science-based and clinically validated eyelash growth treatment.
LATISSE is an easy-to-use treatment that is used once-daily by applying the treatment to the base of the upper eyelashes (like eyeliner) with a sterile single-use-per-eye disposable applicator. In as little as eight weeks, LATISSE users can expect to experience longer, fuller and darker eyelashes, with significant results in 16 weeks.
As part of the FDA prescription-drug approval process, Allergan had to submit well-designed clinical trial protocols to prove efficacy and safety of LATISSE.
LATISSE was found to be well-tolerated with the most commonly reported adverse events being non-serious and cosmetic in nature. Although not observed in the clinical trial, LATISSE solution may cause other less common side effects which typically occur on the skin close to where LATISSE is applied, or in the eyes. These include skin darkening, eye irritation, dryness of the eyes, and redness of the eyelids.
The effects of LATISSE require ongoing treatment be maintained; if treatment is discontinued, eyelashes will gradually return to where they were prior to treatment over a period of weeks to months (average eyelash hair cycle).
So what is the advantage of LATISSE over other eyelash growth products? The fact that Allergan has put this product through rigorous efficacy and safety testing is clearly one advantage. Because LATISSE is a prescription product, you need to discuss it with your doctor, who will determine if you are an appropriate candidate. I’ve tried other non-prescription eyelash growth products with good results and I will probably talk to my doctor about trying LATISSE.
Complete information on LATISSE, including clinical trial and safety data, as well as prescriber information, can be found at www.latisse.com.